Oxidative stress in chronic hepatitis C: The effect of interferon therapy and correlation with pathological features

Canadian Journal of Gastroenterology

Volumn 17, Issue 11, 2003, Pages 644-650

  Serejo, Fátima ^a,c   Emerit, Ingrid ^b   Filipe, Paulo Manuel ^a   Fernandes, Afonso Camilo ^a   Costa, Maria Adília ^a   Freitas, João Pedro ^a   Carneiro de Moura, Miguel ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b SORBONNE UNIVERSITÉ   (France)

^c HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Hepatitis C; Histology; Interferon treatment; Oxidative stress

Indexed keywords

5,5' DITHIOBIS(2 NITROBENZOIC ACID); ALPHA2B INTERFERON; ANTIOXIDANT; BIOLOGICAL MARKER; CLASTOGEN; MALONALDEHYDE; POLYPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; THIOL; THIOL GROUP;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHROMOSOME BREAKAGE; CLASSIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FIBRIN FORMATION; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER FIBROSIS; MALE; METHODOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REFERENCE VALUE; SCORING SYSTEM; TIME;

EID: 0346777284     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/710693     Document Type: Article

References (35)

1. Gonzalez-Peralta R, Davis GL, Lau JYN. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994;21:255-9.
2. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ. Serum malondialdehyde: Possible use for the clinical management of chronic hepatitis C patients. Free Rad Biol Med 1998;25:993-7.
3. Higueras V, Raya A, Rodrigo JM, Serra MA, Romá J, Romero FJ. Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Radic Biol Med 1994;16:131-3.
4. Paradis V, Mathurin P, Kollinger MF, et al. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features. J Clin Pathol 1997;50:401-40.
5. De Maria N, Colantoni A, Fagiuoli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C patients. Free Radic Biol Med 1996;21:291-5.
6. Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxyguanosine, in chronic human liver disease. J Hepatol 2001;35:613-8.
7. Mutlu-Turkoglu U, Ademoglu E, Turkoglu S, Badur S, Uysal M, Toker G. The effects of interferon alpha on serum lipid peroxidation and total content in patients with chronic active hepatitis C. Res Commun Mol Pathol Pharmacol 1997;96:357-61.
8. Beloqui O, Prieto J, Suarez M, Gil B, Quian CH, Garcia N. N-acetil-cysteine enhances the response to interferon alpha in chronic hepatitis C: A pilot study. J Interferon Res 1993;13:279-82.
9. Lim HL, Myers BM, Hamilton BA, Davis GL, Lau JYN. Plasma glutathione concentration in patients with chronic hepatitis C virus infection. J Viral Hepat 1995;2:211-4.
10. Valgimigli M, Gaiani S, Pedulli S, Solendi E Measurement of oxidative stress in human liver by EPR spin probe. Free Radic Res 2000;33:167-78.
11. Bureau C, Bernard J, Chaouche N, et al. Nonstrutural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem 2001;276:23077-83.
12. Boya P, de la Pena A, Beloqui O, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996;23:210-7.
13. Maeda H, Akaike T. Oxygen free radicals as pathogenic molecules in viral diseases. Proc Soc Exp Biol Med 1991;198:721-72.
14. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998;28(Suppl 1):8-13.
15. Riggio O, Montagnese F, Fiore P, et al. Iron overload in patients with chronic viral hepatitis: How common is it? Am J Gastroenterol 1997;92:1298-301.
16. Di Bisceglie A, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomised, controlled trial. Hepatology 2000;32:135.
17. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001;35:297-306.
18. Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radic Biol Med 1997;22:287-305.
19. Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M. Stimulation of collagen α1 (I) gene expression is associated with lipid peroxidation in hepatocellular injury: A link to tissue fibrosis? Hepatology 1994;19:1262-71.
20. Farinati F, Cardin R, Degan P, et al. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. Free Radic Biol Med 1999;27:1284-91.
21. Cardin R, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: Validation in an open population study. J Hepatol 2001;34:587-92.
22. Emerit I, Serejo F, Filipe P, et al. Clastogenic factors as biomarkers of oxidative stress in chronic hepatitis C. Digestion 2000;62:200-7.
23. Serejo F, Costa A, Oliveira AG, Ramalho F, Batista A, Moura MC. Alpha interferon improves liver fibrosis in chronic hepatitis C: Clinical significance of the serum N-terminal propeptide of procollagen type III. Dig Dis Sci 2001;46:1684-9.
24. Sheuer PJ. Classification of chronic viral hepatitis. A need for reassessment. J Hepatol 1991;13:372-4.
25. Emerit I. Clastogenic factors. Detection and assay. Methods Enzymol 1990;186:555-64.
26. Emerit I, Organessian N, Sarkisian T, et al. Clastogenic factors in the plasma of Chernobyl accident recovery workers. Anticlastogenic effect of Ginkgo biloba extract. Radiat Res 1995;144:198-205.
27. Yagi K. Assay for serum lipid peroxide level and its clinical significance. In: Yagi K, ed. Lipid Peroxidation. New York: Academic Press, 1982:223-43.
28. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994;233:380-5.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall LJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
30. Hanigan GE, William BRG. Interferon signalling through arachidonic acid-dependent pathway: A clue to adjuvant therapy for chronic viral hepatitis. Hepatology 1991;14:392-4.
31. Andreoni P, Cursaro, C, Gasbarrini G. Interferonα increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: Can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993;19:228-31.
32. Merritt J, Ball A, Sielaff K, Meltzer D, Borden E. Modulation of 2′, 5′-oligoadenylate Synthetase in patients treated with alpha-interferon: Effects of dose, schedule and route of administration. J Interferon Res 1992;May:7-16.
33. Lotte F, Piton A, Opolon P, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features. J Clin Pathol 1997;50:401-6.
34. Bruno S, Battezzati PM, Bellati G, et al. Long term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001;34:748-55.
35. Emerit I. Reactive oxygen species, chromosome mutations and cancer: Possible role of clastogenic factors in carcinogenesis. Free Rad Biol Med 1994;16:99-109.